New Production Plant in Slovenia is Constructed to Produce Epoetin Alfa

According to this article in in-Pharma Technologists Lek has opened up a manufacturing facility in Slovenia to produce epoetin alfa drug for biosimilars which is marketed by its parent company Sandoz. The addition of the new facility will help boost production of the drug which was originally marketed by Johnson & Johnson.

The huge investment have been used to uild a 430m² production plant that will become a global supply point for Sandoz modified proteins. Zvonko Bogdanovski, a member of the Lek board of management mentions “Our endeavours in biopharmaceuticals will have an important impact on health systems going forward.”

Share this article with your social network, just click below to share now!

Share |